Resources Archive - Page 34 of 47

DDC 2023: Biophysical & Functional Characterization of Bifunctional Small Molecules Enables TPD Drug Discovery

Leverage our platform of biophysical methods to accelerate your research on targeted protein degradation. At DDC 2023, WuXi AppTec scientists...

AACR 2023: Integrated platform enables KRAS-targeted drugs discovery

Discover our end-to-end KRAS services platform presented at AACR 2023! WuXi AppTec scientists have established a comprehensive panel of assays...

AACR 2023: Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma

In our latest AACR poster, WuXi AppTec scientists characterize the therapeutic potential of the antibody-drug conjugate (ADC) polatuzumab vedotin across...

AACR 2023: A tailored platform enables BRAF-targeted drug discovery and precision medicine

In our latest AACR poster, WuXi AppTec scientists showcase the development of a tailored platform of patient-derived xenograft (PDX) models...

Ready-to-Go Biophysical Assays

We offer a comprehensive platform of biophysical screening assays to measure protein binding, thermodynamics, stoichiometry, protein quality, and kinetics to...

Cutting-Edge Crystallography Services

Discover our comprehensive structure generation platform for challenging targets, with our high resolution and high throughput crystallization services to support...

Crystal-Grade Protein Production

With a focus on quality and stability, gain access to our established systems, strategies, and advanced co-expression vectors to address...

Discovery Newsletter: April 2023

In this month’s newsletter, learn more about our comprehensive panel of CDK4/6 inhibitor-resistant breast cancer models and in vitro imaging...

Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of...

Chronic HBV infection (CHB) is a major contributor to liver-related deaths worldwide. The ultimate endpoint of CHB treatment is sustained HBV...

Knowledge Library